Pneumococcal resistance 위험 인자가 있는 경우에 고용량 아목시실린-클라블라네이트(2 g/125 mg extended-release tablets orally twice daily)를 사용합니다.
High-dose high dose amoxicillin-clavulanate (2 g/125 mg extended-release tablets orally twice daily) is appropriate initial therapy for patients who are at higher risk for pneumococcal resistance or poor outcomes (algorithm).
Risk factors for pneumococcal resistance in patients with acute bacterial rhinosinusitis
|
Living in geographic regions with rates of penicillin-nonsusceptible S. pneumonia exceeding 10%* |
|
Age ≥65 years |
|
Hospitalization in the last five days |
|
Antibiotic use in the previous month |
|
Immunocompromise |
|
Multiple comorbidities (eg, diabetes or chronic cardiac, hepatic, or renal disease) |
|
Severe infection (eg, evidence of systemic toxicity with temperature of ≥102°F, threat of suppurative complications) |
* Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.
REF. UpToDate 2019.06.18
'감염내과 > 상기도감염' 카테고리의 다른 글
| 급성 부비동염 치료에서 saline irrigation (0) | 2019.06.18 |
|---|---|
| 급성 부비동염 치료에서 페니실린 알레르기가 있는 경우, Acute rhinosinusitis treatment in patients with penicillin allergy (0) | 2019.06.18 |
| 급성 세균성 부비동염, 치료, Acute bacterial rhinosinusitis, treatment (0) | 2019.06.18 |
| 항히스타민/슈도에페드린, 불면증, Antihistamine/pseudoephedrine, insomnia (0) | 2019.03.29 |
| 백일해의 진단적 접근, Approach to diagnosis, pertussis (0) | 2019.03.29 |
